We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    FSQ02
Previous Study | Return to List | Next Study

Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04210349
Recruitment Status : Completed
First Posted : December 24, 2019
Last Update Posted : November 9, 2022
Sponsor:
Information provided by (Responsible Party):
Sanofi ( Sanofi Pasteur, a Sanofi Company )

Brief Summary:

The primary objectives of the study were:

  • To demonstrate the non-inferiority of the immune response in terms of geometric mean titers (GMTs) and seroconversion rates of the SP Shz QIV compared with the SP Shz TIV containing the Victoria lineage strain (TIV1) and the SP Shz TIV containing the Yamagata lineage strain (TIV2) for each strain
  • To describe the safety profile of each dosage of SP Shz QIV, TIV1 or TIV2

The secondary objectives of the study were:

  • Group 1 (subjects 6-35 months): To demonstrate the superiority of the immune response of SP Shz QIV compared to TIV2 or TIV1 group after the last dose; demonstrate the superiority of the immune response of the 0.5 mL dose of SP Shz QIV compared to 0.25 mL dose of SP Shz QIV group after the last dose; describe the immune response after administration of the last dose of either SP Shz QIV or SP Shz TIV1 or SP Shz TIV2.
  • Groups 2 through 5 (subjects ≥ 3 years): To demonstrate the superiority of the immune response of SP Shz QIV compared to TIV2 or TIV1 group after a single dose; describe the immune response after each and every dose for all subjects ≥ 3 years of either SP Shz QIV or SP Shz TIV1 or SP Shz TIV2
  • Group 2 (subjects 3 to 8 years), previously unvaccinated ,receiving SP Shz QIV: To describe the immune response after administration of each dose of SP Shz QIV, first dose and second dose of SP Shz QIV respectively
  • Group 5 (subjects ≥ 65 years only): To assess the compliance, in terms of immunogenicity, of SP Shz QIV with the requirements of the CHMP NfG CPMP/BWP/214/96 in subjects aged 65 years or older.
  • To describe the safety profile of SP Shz QIV 0.5 mL after each dose.

Condition or disease Intervention/treatment Phase
Influenza Biological: Quadrivalent Influenza Vaccine Biological: Trivalent Influenza Vaccine 1 SP Shz TIV1 Biological: Trivalent Influenza Vaccine 2 SP Shz TIV2 Phase 3

Detailed Description:
Study duration per participants approximately is 180 days

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7106 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: Open-label (single arm for early safety review) in step 1. Modified double-blind in step 2 with an unblinded administrator used at each trial site. The administrator will not be involved in any of the blinded study assessments (e.g., safety).
Primary Purpose: Prevention
Official Title: Immunogenicity and Safety of the Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age
Actual Study Start Date : January 9, 2020
Actual Primary Completion Date : December 1, 2020
Actual Study Completion Date : December 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot Vaccines

Arm Intervention/treatment
Experimental: Group A: 6 to 35 months, previously unvaccinated, step 1
Participants will receive two injections of SP Shz QIV 0.5 mL at Day 0 and Day 28
Biological: Quadrivalent Influenza Vaccine
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Experimental: Group 1: 6 to 35 months, step 2
Participants will receive one injection of SP Shz QIV 0.25 mL or SP Shz QIV 0.5 mL at Day 0 or SP Shz TIV1 0.25 mL or SP Shz TIV2 0.25 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
Biological: Quadrivalent Influenza Vaccine
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Biological: Trivalent Influenza Vaccine 1 SP Shz TIV1
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Biological: Trivalent Influenza Vaccine 2 SP Shz TIV2
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Experimental: Group 2: 3 to 8 years, step 2
Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.
Biological: Quadrivalent Influenza Vaccine
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Biological: Trivalent Influenza Vaccine 1 SP Shz TIV1
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Biological: Trivalent Influenza Vaccine 2 SP Shz TIV2
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Experimental: Group 3: 9 to 17 years, step 2
Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
Biological: Quadrivalent Influenza Vaccine
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Biological: Trivalent Influenza Vaccine 1 SP Shz TIV1
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Biological: Trivalent Influenza Vaccine 2 SP Shz TIV2
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Experimental: Group 4: 18 to 60 years, step 2
Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
Biological: Quadrivalent Influenza Vaccine
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Biological: Trivalent Influenza Vaccine 1 SP Shz TIV1
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Biological: Trivalent Influenza Vaccine 2 SP Shz TIV2
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Experimental: Group 5: >=61 years
Participants will receive one injection of SP Shz QIV 0.5 mL or SP Shz TIV1 0.5 mL or SP Shz TIV2 0.5 mL at Day 0.
Biological: Quadrivalent Influenza Vaccine
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Biological: Trivalent Influenza Vaccine 1 SP Shz TIV1
Pharmaceutical form: Suspension for injection Route of administration: intramuscular

Biological: Trivalent Influenza Vaccine 2 SP Shz TIV2
Pharmaceutical form: Suspension for injection Route of administration: intramuscular




Primary Outcome Measures :
  1. Geometric Mean Titers of Influenza Antibodies for Subjects 6-35 months [ Time Frame: 28 days post-final vaccination ]
    Geometric mean titers will be assessed by a hemagglutination (HAI) method

  2. Participants Achieving Seroconversion Against Antigens for Subjects 6-35 months [ Time Frame: 28 days post-final vaccination ]
    Influenza antibodies will be assessed using the HAI method.

  3. Geometric Mean Titers of Antibodies for Subjects ≥ 3 years [ Time Frame: Day 28 ]
    Geometric mean titers will be assessed by a HAI method

  4. Number of Participants Achieving Seroconversion Against Antigens for Subjects ≥ 3 years [ Time Frame: Day 28 ]
    Influenza antibodies will be assessed using the HAI method.

  5. Number of Participants with Immediate Adverse Events [ Time Frame: Within 30 minutes after vaccination ]
    Immediate adverse events includes unsolicited systemic adverse events occuring within 30 minutes after vaccination

  6. Number of Participants With Solicited Injection Site or Systemic Reactions [ Time Frame: Within 7 days after vaccination ]
    Injection site reactions: injection site tenderness/pain, erythema, swelling, induration, and ecchymosis. Systemic reactions: fever, vomiting, crying abnormal, drowsiness, appetite lost, and irritability for toddlers aged <= 23 months and fever, headache, malaise, myalgia and shivering for participants aged > 2 years.

  7. Number of Participants with Unsolicited Adverse Events [ Time Frame: Within 28 days after vaccination ]
    Adverse events other than solicited reactions

  8. Number of Participants with Serious Adverse Events [ Time Frame: From Day 0 to Day 56 for participants in Group A and from Day 0 to 6 months after last vaccination for participants in Group 1 through Group 5. ]
    Serious adverse events (including adverse event of special interest) are assessed throughout the study.


Secondary Outcome Measures :
  1. Geometric Mean Titers of Antibodies [ Time Frame: Day 0 and 28 days post-final vaccination ]
    Geometric mean titers will be assessed by a HAI method.

  2. Geometric Mean Individual Titer Ratio [ Time Frame: Day 0 and 28 days post-final vaccination ]
    Geometric mean titers will be assessed by a HAI method.

  3. Number of Participants with Detectable Titer ≥ 10 (1/dilution [1/dil]) [ Time Frame: Day 0 and 28 days post-final vaccination ]
    Geometric mean titers will be assessed by an HAI method.

  4. Percentage of Participants with Seroprotection to Antigens After Vaccination [ Time Frame: Day 0 and 28 days post-final vaccination ]
    Seroprotection was defined as antibody titer ≥ 40 (1/dil) on Day 0 and on 28 days post-final vaccination

  5. Percentage of Participants with Seroconversion to Antigens After Vaccination [ Time Frame: Day 0 and 28 days post-final vaccination ]
    Seroconversion titer < 10 (1/dil) on Day 0 and post-injection(s) titer ≥ 40 (1/dil) on Day 28 or Day 56, or titer ≥ 10 (1/dil) on Day 0 and ≥ 4-fold increase of post-injection(s) titer on 28 days post-final vaccination.

  6. Geometric Mean Individual Titer Ratio for Participants Aged 65 years or Older [ Time Frame: Day 0 and 28 days post-final vaccination ]
    Geometric mean titers will be assessed by an HAI method.

  7. Percentage of Participants with Seroconversion to Antigens After Vaccination for Participants Aged 65 years or Older [ Time Frame: Day 0 and 28 days post-final vaccination ]
    Seroconversion titer < 10 (1/dil) on Day 0 and post-injection(s) titer ≥ 40 (1/dil) on Day 28, or titer ≥ 10 (1/dil) on Day 0 and ≥ 4-fold increase of post-injection(s) titer on 28 days post-final vaccination.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria :

  • Aged ≥ 6 months on the day of the first study visit/inclusion
  • In good health or with underlying medical condition(s) that are judged to be stable by the investigator. Medically-stable is defined as:

    • No new diagnosis OR
    • No new class of prescription drug initiated during the 3 months prior to enrollment
  • For participants aged 6 months through 17 years: Informed consent form has been signed and dated by the parent(s) or another legally acceptable representative, if applicable. Additionally an assent form has been signed and dated by the subject if aged 8 through 17 years (based on local regulations). For subjects aged 18 years and above: Informed consent form has been signed and dated
  • Subject / subject and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures
  • For subjects aged 6 months to less than 12 months only: Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg

Exclusion criteria:

  • Subject is pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to vaccination until at least 4 weeks after vaccination. To be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, or surgically sterile
  • Participation at the time of study enrollment (or in the 4 weeks preceding the trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
  • Receipt of any vaccine or planned receipt of any vaccine within the period from 2 weeks before trial vaccination to 2 weeks following trial vaccination (or the last trial vaccination)
  • For previously influenza vaccinated subjects: Previous vaccination against influenza (in the 2019-2020 season) with either the trial vaccine or another vaccine
  • For previously influenza unvaccinated subjects: Any influenza vaccination (from birth to the day of inclusion) with either the trial vaccine or another vaccine
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances
  • Self-reported thrombocytopenia or known thrombocytopenia as reported by the parent/legally acceptable representative, contraindicating intramuscular (IM) vaccination
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
  • Current alcohol abuse or drug addiction
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
  • Personal history of clinically significant developmental delay (at the discretion of the Investigator), neurologic disorder, or seizure disorder
  • Known seropositivity for human immunodeficiency virus, including known HIV carrier or patient
  • Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (axillary temperature ≥ 37.1°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided
  • Personal history of Guillain-Barre syndrome
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04210349


Locations
Layout table for location information
China
Investigational Site Number 1561000
Kunming, China, 650022
Investigational Site Number 1561001
Lincang, China, 677001
Investigational Site Number 1561002
Lincang, China, 677001
Investigational Site Number 1561003
Lincang, China, 677001
Investigational Site Number 1562001
Shangqiu, China, 476000
Investigational Site Number 1562002
Xinxiang, China, 453200
Investigational Site Number 1562000
Zhengzhou, China, 450002
Sponsors and Collaborators
Sanofi Pasteur, a Sanofi Company
Investigators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi Pasteur, a Sanofi Company
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Sanofi Pasteur, a Sanofi Company
ClinicalTrials.gov Identifier: NCT04210349    
Other Study ID Numbers: FSQ02
U1111-1174-4698 ( Other Identifier: UTN )
First Posted: December 24, 2019    Key Record Dates
Last Update Posted: November 9, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Respiratory Tract Infections
Infections
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs